|
Accession number;03A0323480
|
| Title;Pharmacokineties of Pitavastatin (NK-104) Administered for 7-days to Volunteers with Fatty Liver-Pharmacokinetics and Safety of Pitavastatin Administered 2mg Daily for 7-days to 12 Volunteers, 6 with Fatty Liver, 6 Normal- |
| Author;
MORI HARUKI
(Ogikuboichokurinikku)
YAMADA MICHIRU
(Ogikuboichokurinikku)
KATAUMI SEIGO
(Rinshoyakuriigakuken)
MORI MASAKI
(Rinshoyakuriigakuken)
SAITO YASUSHI
(Chibadai Daigakuin'igakukenkyuka Saibouchiryogaku)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.19;NO.4;PAGE.371-379(2003)
|
| Figure&Table&Reference;FIG.5, TBL.8, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In fatty liver group, mean maximum plasma concentration (Cmax) and mean area under the plasma concentration-time curve between 0 to 24 hour (AUC0-24) of pitavastatin and its lactone were slightly lower than normal liver function group on day 1 and day 7. Because body weight in fatty liver group was heavier than that in normal liver function group significantly, we made an analysis of covarience adjusted for body weight. As the result, mean Cmax and mean AUC0-24 of pitavastatin and its lactone were no different among both groups. Adverse reactions were revealed only in one volunteer with S-GPT and S-GOT increased in fatty liver group. (author abst.) |
|
|
|
Related Articles;
|
